Recce Pharmaceuticals Updates Trading Policy
Company Announcements

Recce Pharmaceuticals Updates Trading Policy

Recce Pharmaceuticals Ltd. (AU:RCE) has released an update.

Recce Pharmaceuticals Ltd has announced an amendment to its Securities Trading Policy in line with ASX Listing Rule 12.10, with updated details available on their website. The company, known for developing synthetic anti-infectives aimed at combating antibiotic-resistant superbugs and viral pathogens, has its innovative RECCE compounds recognized by the WHO and granted favorable designations by the FDA. Recce maintains an automated manufacturing process to support ongoing clinical trials of its broad-spectrum anti-infectives targeting unmet medical needs.

For further insights into AU:RCE stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskRecce Pharmaceuticals Advances Phase 3 Trial in Indonesia
TipRanks Australian Auto-Generated NewsdeskRecce Pharmaceuticals Adopts New Constitution Amid Drug Innovation
TipRanks Australian Auto-Generated NewsdeskRecce Pharmaceuticals Advances with Strategic Meeting Outcome
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App